Market Capitalization

With an $80M backlog and a new 'Buy' rating, cybersecurity firm Cycurion looks poised for growth. But can it overcome its volatile past and prove its worth?

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

Amid a historically slow 2025 housing market, proptech firm Orchard reports 40% growth and lands $30M, proving its new marketplace model's resilience.

Powersports giant Massimo Group's stock plummets after announcing a bold but risky plan to acquire an AI firm and enter the health robotics market.

Celanese completes a key divestiture to tackle its massive debt, while buyer Element Solutions bolsters its high-growth electronics portfolio.

Atlantic International hires veteran CFO Kevin J. Murphy to integrate its massive Circle8 acquisition and navigate a complex financial landscape.

The U.S. mortgage insurer completes its $1.67 billion acquisition of a Lloyd's specialist, reshaping its future by betting big on diversification.

Investors sue medical device maker Integer Holdings, alleging misleading statements led to a catastrophic 32% stock drop. What went wrong behind the scenes?

A cancer researcher's 2,115% gain and a Hong Kong trader's 1,499% two-year run redefine market outperformance in the 2025 Investing Championship.

The analytics giant pays down debt and buys back stock, signaling financial health, but faces analyst skepticism over its long-term growth strategy.

Hyperscale Data reaffirms its $100M Bitcoin plan to fund its AI data center, defying a 95% stock drop and major financial red flags. Is it genius or folly?

Facing default, The Cannabist Company secures a short-term forbearance, highlighting a systemic liquidity crisis threatening the US cannabis industry.

Tevogen Bio's stock surged on news of a potential special dividend, but a closer look reveals a risky promise from a pre-revenue firm facing major hurdles.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

As QuantumScape nears commercialization, it adds a veteran CFO from NVIDIA and Cadence to its board, signaling a focus on financial discipline and scaling.

As Ladder Capital preps its 2025 results, investors watch to see if its unique model and fortress balance sheet can defy a volatile market.

With surging revenues and a new body contouring system, Apyx Medical heads to the BTIG conference to prove its growth story is here to stay.

Enveric Biosciences raises $1.5M to advance its novel psychiatric drugs. Is this small cash infusion enough to propel its promising pipeline forward?

Babcock & Wilcox appoints Dr. Homaira Akbari, a tech and AI expert, signaling a major strategic push into powering the booming data center industry.